Review Article

AI in Pharmacovigilance: Enhancing Drug Safety through Intelligent Surveillance

Dr.Ajiith Xavier[1], Dr.Syed Shariq Naeem[2]

1-Junior resident, Department of Pharmacology, JNMCH,

2--Assistant professor, Department of Pharmacology, JNMCH

e-mail: ajiithxavier96@gmail.com

ABSTRACT

Introduction: *Pharmacovigilance (PV) plays a key role in the healthcare system through the assessment, monitoring, and discovery of drug interactions and their effects in humans. It concerns the detection, assessment, understanding, and prevention of ADRs. Due to the vast quantities and complexity of data to be analyzed, computational methods that can accurately detect ADRs in a timely fashion have become a critical component in PV. This prompted the exploration of Artificial Intelligence (AI) applications to enhance pharmacovigilance practices.*

Aims and Objective*: To explore the types and methods of AI technologies in pharmacovigilance, assessing their potential to improve the efficiency, accuracy, and timeliness of adverse event detection and analysis.*

Methods: *This literature review was done by searching articles in databases like PUBMED, EMBASE, SCOPUS, and COCHRANE database. The search was made using "artificial intelligence"; "pharmacovigilance"; "machine learning"; "Deep learning"; "Adverse drug reaction"; "case reporting" as the keywords.*

Results: *AI applications in pharmacovigilance offer rapid identification of potential safety signals, early detection of emerging risks, and improved comprehension of intricate drug-event relationships. Methods like SHAP (Shapley Additive Explanations) and LIME (Local Interpretable Model-Agnostic Explanations) can be used in pharmacovigilance assessments of drug safety and to understand the causes of side effects. Automation of routine tasks enables pharmacovigilance professionals to dedicate more time to in-depth analysis and decision-making.*

Conclusion*: The implementation of AI in pharmacovigilance has significant implications for proactive and personalized drug safety monitoring. While AI holds great promise in advancing pharmacovigilance, challenges such as algorithm validation, transparency, and ethical considerations must be addressed. Collaboration among stakeholders is crucial to harness the full potential of AI in enhancing drug safety.*

How to cite this article: Tiwari A, Jain S, Khan IA, Khan FA, Zubair MY. Adverse Events Following Vaccination with COVID-19 Vaccines: A Narrative Review. J Pharmacovig Drug Safety 2023;20(2):1-5.

Source of Support: Nil, **Conflict of Interest:** None

INTRODUCTION

The term "Pharmacovigilance" originates from the Greek word "pharmakon" (meaning drug) and the Latin word "vigilare" (meaning keep watch). Initiated by the thalidomide disaster in 1961, the World Health Organization (WHO) established the pharmacovigilance (PV) program for global drug monitoring. Pharmacovigilance involves monitoring, evaluating, and reporting drug side effects. Despite rigorous pre-clinical and clinical testing, absolute safety cannot be guaranteed post-market. Post-marketing PV relies on tools like data mining and case report investigations to identify relationships between drugs and adverse drug reactions (ADRs).

EXISTING TOOLS IN PHARMACOVIGILANCE

- **VigiBase**: A structured PV database with over 20 million adverse drug effect reports.
- **VigiAccess:** A publicly accessible web application for easy access to VigiBase data.

- **VigiLyze:** An online resource for a quick review of VigiBase, available for further analysis.
- **VigiFlow**: A web-based ICSR management system supporting international drug monitoring.
- **VigiGrade:** Measures completeness of clinically relevant information in individual case reports.
- **VigiMatch:** An algorithm for detecting similar individual case reports through probabilistic pattern matching.
- **VigiRank:** A novel method to detect statistical signals in reporting patterns, completeness, recency, and geographic spread.

HOW PHARMACOVIGILENCE WORKS



Figure 1: Flow of events in Pharmacovigilance

ARTIFICIAL INTELLIGENCE IN PHARMACOVIGILANCE

In developing countries, Pharmacovigilance (PV) remains a novel concept with limited adoption. Globally, nations are expressing concerns about the necessity for systems to oversee the safety of drugs post-marketing. Adverse drug reaction (ADR) reporting primarily occurs through spontaneous reporting or pharmacoepidemiological methods involving the systematic collection and analysis of adverse events (AE)

linked to drug usage. Adverse Drug Reaction Monitoring Centres and marketing authorization holder (MAH) industries also play a role in addressing emerging issues, recording signals, and communicating to minimize or prevent harm.[1]

The human fascination with replicating human intelligence in machines is not a new phenomenon; it has evolved over time. Presently, various information systems groups are actively developing learning algorithms to emulate human learning and decision-making processes.[2] Artificial Intelligence (AI), as a technology, is at the forefront of tools that can significantly enhance the rapid and accurate detection of drug side effects.[3]

In pharmacovigilance, the integration of AI is expanding across different domains, including safety operations, signal management, and the identification of target populations. Understanding the current landscape of AI in pharmacovigilance is crucial, along with recognizing opportunities for further advancements in this field.[2]

Current methods in adverse drug reaction (ADR) extraction often rely on supervised learning, facing challenges related to the scarcity of labeled data. AI, with its distinctive features such as machine learning (ML) and natural language processing (NLP), addresses these issues. ML techniques are adept at analyzing structured data like imaging and genetic information, while NLP excels in understanding and interpreting unstructured free-text forms, reflecting human language nuances.[1]

BENEFITS OF ARTIFICIAL INTELLIGENCE IN PHARMACOVIGILANCE

- Reduced cycle times for spontaneous processing.
- They have improved the quality and accuracy of information.
- Handling diverse data formats.
- Identification of ADRs.
- Reduced burden and time in case processing.
- Extraction of information from adverse drug event forms without manual intervention.

METHODS IN ARTIFICIAL INTELLIGENCE

- Natural Language Processing (NLP)
- Machine Learning (ML)
- Artificial Neural Networks (ANN)
- Decision Trees
- Data Mining
- Deep Learning

Utilizing social media as a platform for postmarket surveillance proves advantageous due to its extensive audience and widespread reach. These platforms play a crucial role in real-time information retrieval and trend tracking, including the monitoring of digital disease surveillance systems. Recent research highlights Twitter as a particularly valuable source, reporting three times more Adverse Drug Reactions (ADRs) than the FDA. Out of 61,000 collected tweets, 4400 referenced ADRs, surpassing the 1400 ADRs reported through the FDA within the same timeframe. This underscores the potential of Twitter for establishing a real-time post-marketing drug safety surveillance system.[4]

In the context of explainable AI, methods such as Shapley Additive Explanations (SHAP) and Local Interpretable Model-Agnostic Explanations (LIME) can be applied in pharmacovigilance assessments of drug safety. These approaches contribute to a comprehensive understanding of the causes behind side effects.[3]

LIMITATIONS:

- **Lack of data**: Missing data may lead to inaccurate results.
- **Data illusion**: AI technologies can be misleading in detecting side effects.
- **Bias**: AI accuracy may be compromised if data used are biased.

DISCUSSION

Research in the intersection of AI and pharmacovigilance reveals its potential in swiftly and accurately detecting drug side effects. These technologies prove highly efficient in analyzing extensive datasets, enabling the early identification of potential risks associated with side effects. Moreover, AI applications offer enhanced precision in the analysis of side effects, contributing to a deeper understanding of their nature.[3]

The collaboration between IT firms and pharmaceutical companies plays a pivotal role in influencing these advancements. This partnership has the potential to enhance regulatory compliance, achieve cost reductions, and bring about other positive outcomes for pharmaceutical and medical device companies (1). In the context of the Pharmacovigilance Program of India (PvPI), the overall process, from case receipt to reporting, can be alleviated through automated input facilitated by AI techniques. This not only reduces costs but also enhances the quality and accuracy of the pharmacovigilance process.[1]

The synergistic use of machine learning and Natural Language Processing (NLP) techniques holds promise in providing accurate outputs, thereby augmenting the rapid and precise processing of spontaneous Individual Case Safety Reports (ICSRs) by pharmacovigilance professionals. The integration of big data technology further enhances drug safety monitoring in clinical settings, aiding pharmacovigilance professionals in forming targeted hypotheses related to Adverse Drug Events (ADEs) resulting from drug–drug interactions.(1) Existing studies underscore the potential impact of machine learning in pharmacovigilance efforts, with the effectiveness contingent upon the type of database or source being utilized. These machine learning methods offer potential improvements in accuracy, automation, and the comprehensiveness of evaluating patient safety events.[4]

CONCLUSION

In conclusion, the potential applications of artificial intelligence in pharmacovigilance and patient safety extend beyond the scope outlined in this review, particularly as individuals become more acquainted with AI methodologies. The evolution of drug safety strategies in the future may witness advancements propelled by the integration of AI techniques. Further research is imperative in the field of AI concerning pharmacovigilance. Currently, AI, databases, and associated tools are in their early developmental stages, indicating the promising potential for future advancements in the field of pharmacovigilance.

REFERENCE

1. Murali K, Kaur S, Prakash A, Medhi B. Artificial intelligence in pharmacovigilance: Practical utility. Indian J Pharmacol. 2019;51(6):373.
2. Salas M, Petracek J, Yalamanchili P, Aimer O, Kasthuril D, Dhingra S, et al. The Use of Artificial Intelligence in Pharmacovigilance: A Systematic Review of the Literature. Pharm Med. 2022 Oct;36(5):295–306.
3. Kırboğa KK, Çiftçi B, Işık M. An Overview of Artificial Intelligence and Explainability in Pharmacovigilance.
4. Gupta S, Pawar S, Ramrakhiyani N, Palshikar GK, Varma V. Semi-Supervised Recurrent Neural Network for Adverse Drug Reaction mention extraction. BMC Bioinformatics. 2018 Jun;19(S8):212.